TORONTO, and CHENNAI, India, May 11 /PRNewswire/ -- Dalton Pharma Services and ProCitius Research jointly announce a strategic alliance created to provide clients with contract chemistry services of exceptional value.
Global pharmaceutical companies, in order to maintain their discovery and development output in an era of severe cost restraints, have been increasing their use of "offshore" contract research organizations (CROs) in countries such as China and India. Despite the quality of chemists in offshore CROs, there are often performance issues caused by communication and cultural differences. In order to ensure quality and timeliness in the contracted work, pharmaceutical companies are usually forced to dedicate senior staff to manage these projects on-site or from Western research centers.
Dalton and ProCitius have teamed up to offer clients the best of both worlds. Projects carried out by ProCitius in India are tightly controlled by senior Dalton project managers based at the company headquarters in Canada. Clients deal only with Dalton, which assumes full legal and operational responsibility for the satisfactory execution of the contract. The contract pricing is based on attractive FTE rates.
"I believe this type of hybrid service fills an important need in our industry," said Peter Pekos, President and CEO of Dalton Pharma Services. "Over the past two decades I have worked to adjust our service offering to meet the changing requirements of my clients and today's announcement is part of this continuing evolution," he continued. "In ProCitius we have the ideal partner: well-established; large FTE headcount; excellent facilities and infrastructure; robust documentation; and a reputation for high ethical and environmental standards."
|SOURCE Dalton Pharma Services|
Copyright©2009 PR Newswire.
All rights reserved